Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, vol.18, issue.5, pp.623-653, 2017. ,
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.13, issue.24, pp.2342-50, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02284390
PD1 signal transduction pathways in T cells, Oncotarget. 1 août, vol.8, issue.31, pp.51936-51981, 2017. ,
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol. 1 mai, vol.28, issue.13, pp.2181-90, 2010. ,
Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity, J Immunother. avr, vol.38, issue.3, pp.116-142, 2015. ,
The biological rationale for immunotherapy in cancer, Rev Mal Respir. févr, vol.35, issue.2, pp.206-228, 2018. ,
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy, Lung Cancer. janv, vol.71, issue.1, pp.75-81, 2011. ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Functional differences between low-and high-affinity CD8+ T cells in the tumor environment, OncoImmunology, vol.1, issue.8, pp.1239-1286 ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study, Lancet Respir Med, vol.6, issue.6, pp.451-60, 2018. ,
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study, J Thorac Oncol. juill, vol.14, issue.7, pp.1233-1276, 2019. ,
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.21, pp.2027-2066, 2018. ,
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma, Lung Cancer. févr, vol.83, issue.2, pp.240-245, 2014. ,
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, New England Journal of Medicine. 22 juin, vol.376, issue.25, pp.2415-2441, 2017. ,
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma, J Clin Oncol. 20 mars, vol.24, issue.9, pp.1443-1451, 2006. ,
Oncology meets immunology: the cancer-immunity cycle, Immunity. 25 juill, vol.39, issue.1, pp.1-10, 2013. ,
comité de rédaction des référentiels Auvergne Rhône-Alpes en oncologie thoracique. Référentiel sur le cancer bronchique non à petites-cellules : actualisation 2019, 2019. ,
Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Résultats préliminaires. Rapport. Saint-Maurice (Fra) : Santé publique France, 2019. ,
Toxicity of immune checkpoints inhibitors, Rev Mal Respir. déc, vol.35, issue.10, pp.1028-1066, 2018. ,
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group, Thorax. févr, vol.71, issue.2, pp.177-84, 2016. ,
, , pp.7-8
, T-cell apoptosis: a potential mechanism of immune evasion, Nat Med. août, vol.8, issue.8, pp.793-800, 2002.
Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002. ,
The three Es of cancer immunoediting, Annu Rev Immunol, vol.22, pp.329-60, 2004. ,
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med, vol.30, issue.9, p.14, 2018. ,
Use of Immune Checkpoint Inhibitors in Mesothelioma, Curr Treat Options Oncol. 14 févr, vol.20, issue.2, p.18, 2019. ,
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, Journal of experimental Medicine, vol.206, issue.13, pp.3015-3044 ,
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, vol.192, issue.7, pp.1027-1061, 2000. ,
The immune microenvironment of human tumors: general significance and clinical impact, Cancer Microenviron. août, vol.6, issue.2, pp.117-139, 2013. ,
Alectinib versus crizotinib in treatmentnaive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study, Ann Oncol, vol.29, issue.11, pp.2214-2236, 2018. ,
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer, J Clin Oncol, vol.34, issue.34, pp.4079-85, 2016. ,
Molecular Mechanisms of Resistance to First-and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer, 18 juill, vol.6, issue.10, pp.1118-1151, 2016. ,
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis, Clin Cancer Res. 15 sept, vol.22, issue.18, pp.4585-93, 2016. ,
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents, Cancer Cell. 14 déc, vol.28, issue.6, pp.690-714, 2015. ,
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria, Eur J Cancer, vol.82, pp.27-33, 2017. ,
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, New England Journal of Medicine. 16 avr, vol.378, issue.22, pp.2078-92, 2018. ,
Radiotherapy for primary lung carcinoma, Cancer Radiother. sept, vol.20, pp.147-156, 2016. ,
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol. déc, vol.17, issue.12, pp.1643-52, 2016. ,
Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management, Am Soc Clin Oncol Educ Book. 23 mai, vol.38, pp.13-22, 2018. ,
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy, Immunity. avr, vol.28, issue.4, pp.571-80, 2008. ,
,
, Bull Cancer. mars, vol.104, issue.3, pp.245-57, 2017.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): doseexpansion cohort of a multicentre, open-label, phase 1b trial, Lancet Oncol, vol.18, issue.5, pp.599-610, 2017. ,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.29, issue.4, pp.264-270, 2018. ,
Hallmarks of cancer: the next generation, Cell. 4 mars, vol.144, issue.5, pp.646-74, 2011. ,
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, Lancet Oncol, vol.18, issue.1, pp.31-41, 2017. ,
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.23, pp.2220-2229, 2018. ,
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, vol.31, issue.6332, pp.1428-1461, 2017. ,
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group, Arch Pathol Lab Med. janv, vol.142, issue.1, pp.89-108, 2018. ,
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas, Am J Surg Pathol. mai, vol.40, issue.5, pp.714-722, 2016. ,
, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking, IARC Monogr Eval Carcinog Risks Hum, vol.83, pp.1-1438, 2004.
, Cancer broncho-pulmonaire : Du diagnostic au suivi, 2016.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade, N Engl J Med, vol.375, issue.18, pp.1749-55, 2016. ,
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients, Journal of Thoracic Oncology. 24 févr, vol.14, issue.6, pp.963-970, 2019. ,
Adaptive immunity maintains occult cancer in an equilibrium state, Nature. 6 déc, vol.450, issue.7171, pp.903-910, 2007. ,
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to, Int J Radiat Oncol Biol Phys. 1 déc, vol.65, issue.5, pp.1595-1601, 2006. ,
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, vol.17, issue.11, pp.1497-508, 2016. ,
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, J Clin Oncol. 10 juin, vol.33, issue.17, pp.1958-65, 2015. ,
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement, J Clin Oncol. 10 août, vol.35, issue.23, pp.2613-2621, 2017. ,
comité de rédaction des référentiels Auvergne Rhône-Alpes en, et al. Référentiel sur le Mésothéliome Malin de la plèvre : actualisation 2019, 2019. ,
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial, Lancet Oncol, vol.18, issue.9, pp.1261-73, 2017. ,
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors, Eur J Cancer, vol.82, pp.128-164, 2017. ,
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC, J Thorac Oncol, vol.12, issue.2, pp.194-207, 2017. ,
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort, Journal of Clinical Oncology. 20 mars, vol.33, issue.9, pp.992-1001, 2015. ,
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series, Eur J Cancer. déc, vol.105, pp.88-102, 2018. ,
A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions, Chem Res Toxicol. févr, vol.21, issue.2, pp.494-502, 2008. ,
Malignant mesothelioma and constitutional BAP1 gene mutations, Rev Mal Respir. févr, vol.36, issue.2, pp.241-249, 2019. ,
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma, Br J Cancer. 27 août, vol.87, issue.5, pp.491-497, 2002. ,
, Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, NSCLC Meta-analysis Collaborative Group, vol.383, pp.1561-71, 2014.
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset, Jpn J Clin Oncol. 1 janv, vol.49, issue.1, pp.29-36, 2019. ,
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann Oncol, vol.01, issue.3, pp.583-592, 2017. ,
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma, J Clin Oncol, vol.36, issue.28, pp.2863-71, 2018. ,
Surgery and mesothelioma: if not randomization, at least standardization and registration! Lung Cancer, janv, vol.71, issue.1, pp.1-2, 2011. ,
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A, Cell Cycle. 1 déc, vol.11, issue.23, pp.4305-4314, 2012. ,
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.21, pp.2040-51, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02345238
Treatment Outcomes of Immune-Related Cutaneous Adverse Events, J Clin Oncol, 2019. ,
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J Clin Oncol. 20 juill, vol.26, issue.21, pp.3552-3561, 2008. ,
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.29, issue.Supplement_4, pp.192-237, 2018. ,
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 30 janv, 2019. ,
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an openlabel, multicentre phase 2 trial, Lancet Oncol. juill, vol.17, issue.7, pp.984-93, 2016. ,
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an openlabel, phase 2 trial, Lancet Oncol, vol.18, issue.10, pp.1307-1323, 2017. ,
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers, J Clin Oncol. 20 avr, vol.37, issue.12, pp.992-1000, 2019. ,
Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncology, vol.8 ,
,
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer, J Clin Oncol, vol.01, issue.31, pp.3740-3748, 2016. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.10, issue.19, pp.1823-1856, 2016. ,
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial, Eur J Cancer. juill, vol.116, pp.137-184, 2019. ,
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma, Int J Radiat Oncol Biol Phys, vol.69, issue.2, pp.350-357, 2007. ,
Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group, J Thorac Oncol. août, vol.6, issue.8, pp.1304-1316, 2011. ,
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases, Cancer. 15 mars, vol.116, issue.6, pp.1510-1517, 2010. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, vol.21, pp.255-65, 2017. ,
Advances in malignant mesothelioma, N Engl J Med, vol.353, issue.15, pp.1591-603, 2005. ,
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers, Ann Oncol, vol.29, issue.10, pp.2085-91, 2018. ,
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study, Lancet Oncol, vol.19, issue.12, pp.1579-89, 2018. ,
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program, J Thorac Oncol. juill, vol.3, issue.7, pp.756-63, 2008. ,
Correlation between immunerelated adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer, vol.115, pp.71-75, 2018. ,
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol. 20 juill, vol.26, issue.21, pp.3543-51, 2008. ,
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol. févr, vol.20, issue.2, pp.239-53, 2019. ,
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med. 10 janv, vol.346, issue.2, pp.92-100, 2002. ,
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science. 25 mars, vol.331, issue.6024, pp.1565-70, 2011. ,
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, Nat Immunol. mars, vol.8, issue.3, pp.239-284, 2007. ,
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm firstin-man phase 1 trial, Lancet Oncol, vol.18, issue.12, pp.1590-1599, 2017. ,
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett. 10 sept, vol.574, issue.1-3, pp.37-41, 2004. ,
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med. 14 juin, vol.378, issue.24, pp.2288-301, 2018. ,
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, New England Journal of Medicine. 4 déc, vol.371, issue.23, pp.2167-77, 2014. ,
Systematic review and metaanalysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as firstline treatment in patients with advanced non-small-cell lung cancer, Ann Oncol. janv, vol.24, issue.1, pp.20-30, 2013. ,
First-line ceritinib versus platinumbased chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, vol.04, pp.917-946, 2017. ,
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation -Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370), J Thorac Oncol, vol.13, issue.5, pp.682-690, 2018. ,
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma, Lung Cancer. janv, vol.63, issue.1, pp.94-101, 2009. ,
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy, J Thorac Oncol. mars, vol.14, issue.3, pp.494-502, 2019. ,
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma, Ann Thorac Surg. févr, vol.99, issue.2, pp.472-80, 2015. ,
Effects of marijuana smoking on the lung, Ann Am Thorac Soc. juin, vol.10, issue.3, pp.239-286, 2013. ,
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study, J Thorac Oncol, vol.12, issue.12, pp.1798-805, 2017. ,
Management of immune related adverse events induced by immune checkpoint inhibition, Cancer Lett. 1 août, vol.456, pp.80-87, 2019. ,
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart, J Thorac Oncol. sept, vol.10, issue.9, pp.1240-1242, 2015. ,
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol. août, vol.12, issue.8, pp.763-72, 2011. ,
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma, Br J Cancer. 1 févr, vol.86, issue.3, pp.342-347, 2002. ,
Natural innate and adaptive immunity to cancer, Annu Rev Immunol, vol.29, pp.235-71, 2011. ,
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol. 15 juill, vol.21, issue.14, pp.2636-2680, 2003. ,
Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-71, 1960. ,
NK cells and cancer immunosurveillance, Oncogene, vol.27, issue.45, pp.5932-5975, 2008. ,
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, JAMA Oncol. 1 déc, vol.4, issue.12, pp.1721-1729, 2018. ,
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance, Nature. 1 sept, vol.437, issue.7055, pp.141-147, 2005. ,
Therapeutic management options for stage III non-small cell lung cancer, World J Clin Oncol. 10 févr, vol.8, issue.1, pp.1-20, 2017. ,
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet. 2 avr, vol.387, pp.1405-1419, 2016. ,
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey, Lung Cancer. mars, vol.75, issue.3, pp.360-367, 2012. ,
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2, J Clin Oncol. 10 août, vol.31, issue.23, pp.2849-53, 2013. ,